Open Access Critical Evidence Review

Glycemic variability: adverse clinical outcomes and how to improve it? - A review of the evidence

The study examines why wide glycemic fluctuations may add information to average glycemia. Independent literature primarily confirms an association with a higher risk of severe hypoglycemia and signs of oxidative stress. Associations with vascular complications remain less uniform and require prospective and interventional confirmation in humans to define their clinical causality.

Cite this article
Iodice, D. (2026). Glycemic variability: adverse clinical outcomes and how to improve it? - A review of the evidence. Life Science Hub Journal. DOI: 10.5281/zenodo.24202469. https://lifesciencehub.info/en/glycemic-variability-adverse-clinical-outcomes-and-how-to-improve-it-a-review-of-the-evidence
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24202469

Article history
Dates
  • Published 13/11/2026
  • Updated 13/11/2026
Revisions
  1. v1.0 — 13/11/2026 Initial publication of the article.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Scientific still life with continuous glucose monitoring, healthy foods, and glycemic curves, to explain glycemic variability and the risk of hypoglycemia.
Continuous glucose monitoring, glycemic fluctuations, and clinical tools in a scientific context: the image highlights the value of glycemic stability beyond the average alone.

ABSTRACT

The analyzed publication is a narrative review examining glycemic variability, i.e., the magnitude and frequency of blood glucose fluctuations, both throughout the day and between different visits. The authors describe observational and experimental studies in which greater glycemic instability has been associated with hypoglycemia, microvascular and macrovascular complications, mortality, and other adverse outcomes. The review also discusses the contribution of continuous glucose monitoring, medications, diet, and exercise to reducing these fluctuations.

In section 3.1 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the study contributes to two specific points: the hypothesis that rapid fluctuations may promote oxidative stress and the fact that glycemic variability can help identify a higher risk of severe hypoglycemia beyond glycated hemoglobin alone. Independent evidence directly confirms the association between greater variability and an increased risk of hypoglycemia in type 1 diabetes; a human study also finds a correlation between acute fluctuations and a urinary marker of oxidative stress. However, these data do not prove that variability alone causes all diabetic complications. An analysis of the Diabetes Control and Complications Trial did not observe an independent contribution of intraday variability to microvascular complications after adjustment for mean glycemia. Overall, the narrative is moderately supported, especially regarding the assessment of hypoglycemic risk.

Analyzed study

Glycemic variability: adverse clinical outcomes and how to improve it?

Zhou Z, Sun B, Huang S, Zhu C, Bian M

Cardiovascular diabetology, 2020

DOI: 10.1186/s12933-020-01085-6

PMID: 32622354

PMCID: PMC7335439

The research question was whether glycemic variability, in addition to mean glycemia and glycated hemoglobin or HbA1c (an index of the average glycemia over the last two to three months), is linked to unfavorable clinical outcomes and which tools can reduce it. The underlying hypothesis is that it is not only important how high the glycemia is on average, but also how frequently and how rapidly it increases or decreases.

The relevance to paragraph 3.1 is precise. The publication was used to support the claim that marked fluctuations can be biologically relevant and that variability indices help estimate the risk of hypoglycemia, often in a complementary way to HbA1c. Being a narrative review, the analyzed study synthesizes results from previous research but does not produce a new experimental comparison or a new patient cohort. It can therefore describe the convergence of the available literature, but cannot by itself demonstrate a causal relationship between glycemic variability and individual complications.

Materials and methods of the original study

The publication is a narrative review of the literature, not a clinical study with participants enrolled directly by the authors. The text distinguishes between short-term variability, observable within a single day or between consecutive days, and long-term variability, calculated through repeated measurements of fasting glycemia, post-meal glycemia, or HbA1c.

Several indicators are described. The standard deviation indicates how much values deviate from their mean. The coefficient of variation relates this dispersion to the mean glycemia. MAGE quantifies the amplitude of major excursions between peaks and nadirs. Continuous glucose monitoring, or CGM, detects frequent values in the interstitial fluid and allows for a more detailed observation of the daily profile compared to point-in-time measurements.

The available material does not report a reproducible bibliographic search strategy, the databases consulted, formal inclusion or exclusion criteria for the studies, a standardized risk-of-bias assessment, or a quantitative meta-analysis. Consequently, it is not possible to establish with precision how all the discussed studies were selected, nor to formally estimate the heterogeneity of the results.

Results

The review reports that greater glycemic variability has been associated, in various studies, with a higher frequency of hypoglycemia, less favorable cardiovascular and microvascular outcomes, and increased mortality. The authors emphasize that HbA1c represents an average value and may not show the fluctuations between glycemic peaks and rapid drops in glycemia.

Regarding the relevant passage in the book, the central finding is that indices such as standard deviation, coefficient of variation, MAGE, and glycemic risk indices have been repeatedly associated with a higher probability of hypoglycemia. The review also highlights that CGM allows for the recognition of nocturnal and post-meal oscillations, phenomena that isolated measurements may fail to detect.

The text also examines the possible biological link between rapid glucose oscillations and oxidative stress, which is an imbalance where the production of oxidizing molecules exceeds the body's defenses. However, the publication does not provide a single overall quantitative estimate of the effect, because it collects studies with different populations, metrics, and observation periods. It does not report its own sample size, follow-up, or original statistical values, as it is neither an intervention study nor a meta-analysis.

Interpretation

In simple terms, two people can have the same HbA1c but very different daily patterns: relatively stable glycemia or frequent ups and downs. The publication analyzed argues that this second piece of information can be clinically useful, especially when it is necessary to identify those most at risk for episodes of excessively low blood sugar.

The segment of the scientific chain effectively documented by the review is: wider glycemic oscillations → greater exposure to extreme values and greater association with hypoglycemia; in parallel, acute oscillations → association with markers of oxidative stress. The review proposes that oxidative stress, inflammation, and vascular alterations may contribute to complications, but this sequence has not been demonstrated in a causal and uniform manner in humans.

The most solid point, therefore, is not the claim that reducing variability necessarily prevents all diabetic complications. It is rather the recognition that glycemic stability adds information beyond the average alone and that high variability can signal a greater risk of hypoglycemia. The strength of the interpretation changes based on the context: type of diabetes, insulin therapy, indicator used, and quality of the measurement.

Independent confirming evidence

Direct confirmation of the passage regarding hypoglycemia comes from a new analysis of data from the Diabetes Control and Complications Trial. In this cohort of people with type 1 diabetes, Kilpatrick and colleagues evaluated whether mean glycemia and intraday glycemic variability added information to HbA1c in predicting episodes of severe hypoglycemia. After adjusting for HbA1c, each 1 mmol/L increase in the glycemic standard deviation was associated with a 1.09-fold increase in the risk of a first severe episode; for the fifth episode, the ratio rose to 1.12. This is a prognostic association, not proof that variability causes hypoglycemia, but it confirms that HbA1c alone does not exhaust the risk assessment [1].

For the mechanistic passage, Monnier and colleagues compared 21 people with type 2 diabetes and 21 controls matched for age and sex. In participants with diabetes, a greater amplitude of glycemic excursions, measured with MAGE via CGM, was associated with higher urinary excretion of 8-iso-prostaglandin F2a, an indicator of oxidative stress. The correlation between MAGE and this marker was positive and strong, with r=0.86 and P<0.001. The study confirms the biological consistency of the narrative, but the case-control design and the small sample size do not allow for proof that oscillations are the cause of vascular complications [2].

The two studies are independent of the publication analyzed and support different parts of the same narrative: the first concerns the clinical prediction of severe hypoglycemia, the second a possible biological mechanism of glycemic oscillations. Together, they reinforce the idea that monitoring glycemic stability can complement, without replacing, mean glycemia and HbA1c.

Conflicting evidence

Significant conflicting evidence concerns the relationship between glycemic variability and microvascular complications. In the Diabetes Control and Complications Trial, Lachin and colleagues analyzed intraday and inter-visit glycemic variations in people with type 1 diabetes. After adjusting for mean glycemia, no measure of intraday variability was found to be associated with the development or progression of retinopathy, nephropathy, or cardiovascular autonomic neuropathy. The authors therefore concluded that the available glycemic profiles did not provide strong and consistent evidence of an independent effect of variability on microvascular complications [3].

This result does not contradict the association between variability and the risk of hypoglycemia, as the outcomes are different. However, it reduces the certainty of the broader idea that high oscillations directly cause all diabetes complications. Furthermore, the study used seven-point quarterly glycemic profiles rather than modern CGM: while this may limit the ability to detect short excursions, it does not justify ignoring the negative result.

Summary table of evidence

The table distinguishes the publication reviewed from the independent research used to confirm or define the book's narrative progression.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Narrative review Literature on diabetes, CGM, and glycemic variability Synthesizes associations between high variability, hypoglycemia, complications, and mortality; discusses potential reduction strategies. biologically consistent evidence moderate
[1] Observational, new cohort analysis People with type 1 diabetes from the Diabetes Control and Complications Trial Higher glycemic standard deviation associated with increased risk of repeated episodes of severe hypoglycemia, even after adjustment for HbA1c. direct confirmation moderate
[2] Case-control 21 people with type 2 diabetes and 21 controls Higher MAGE associated with greater urinary excretion of an oxidative stress marker. indirect confirmation preliminary
[3] Observational, longitudinal analysis People with type 1 diabetes from the Diabetes Control and Complications Trial After adjustment for mean glycemia, intraday variability was not associated with the microvascular complications analyzed. discordant evidence moderate

Confirmation of the evidence

Claim in the book

In section 3.1 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, glycemic variability is described as a factor that can provide additional information beyond average glycemia. The text further states that the alternation between hyperglycemic peaks and rapid reductions can promote oxidative stress and that greater variability is one of the best predictors of the risk of severe hypoglycemia, often more informative than HbA1c alone.

Wide glycemic fluctuations → exposure to extreme values and oxidative stress → increased risk of hypoglycemia and potential biological damage

The publication subject to the Evidence Review was used in the book to support the following point: glycemic variability is not the same as average glycemia, it can be associated with unfavorable biological processes, and it can help identify the risk of severe hypoglycemia beyond HbA1c alone.

The correspondence between the analyzed publication and the paragraph is clear because the review synthesizes the very studies that link indices of glycemic variability, hypoglycemia, and potential mechanisms of damage. Independent confirmation is more direct for the clinical branch of the chain: in type 1 diabetes, a higher standard deviation of glycemia has been associated with a greater risk of severe hypoglycemia, even after accounting for HbA1c [1]. For the biological branch, a case-control study in humans found that wider acute oscillations were associated with a higher urinary marker of oxidative stress [2].

However, the narrative in “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi requires an essential distinction: the association with hypoglycemia is better supported than the hypothesis that variability autonomously causes all vascular complications. In fact, a longitudinal analysis in type 1 diabetes did not find an independent association between intraday variability and the progression of microvascular complications after adjustment for mean glycemia [3]. The literature therefore confirms the complementary value of glycemic stability in risk assessment, but does not allow for the attribution of a universal causal role to variability.

Overall level of confirmation

MODERATE CONFIRMATION

The publication subject to the review is consistent with the book excerpt, and independent studies directly confirm the association between higher glycemic variability and increased risk of hypoglycemia. The link with oxidative stress is biologically plausible but based on small observational data, while the independent effect on microvascular complications remains controversial.

Conclusions

The analyzed publication consistently supports the idea that average glycemia does not fully describe metabolic control. The best-supported part of the narrative concerns the relationship between greater glycemic variability and a higher risk of severe hypoglycemia, particularly in people treated with insulin. The link between acute fluctuations and oxidative stress is supported at an observational and mechanistic level, but requires validation in larger studies. Conversely, it has not been uniformly demonstrated that reducing variability, independently of average glycemia, prevents all microvascular or cardiovascular complications.

Overall assessment

The narrative is moderately supported. The value of glycemic variability as a complement to HbA1c and as an indicator of higher hypoglycemic risk is fairly well supported. The mechanism of oxidative stress is biologically consistent, but its independent causal role in vascular complications remains less defined and context-dependent.

References

[1] Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes

Kilpatrick ES, Rigby AS, Goode K, Atkin SL, 2007

Diabetologia

[2] Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al., 2006

JAMA

[3] Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, et al., 2017

Diabetes Care

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.